Last update Oct. 12, 2022
Very High Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Amfepramone Hydrochloride is also known as
Amfepramone Hydrochloride in other languages or writings:
Amfepramone Hydrochloride belongs to these groups or families:
|T½||4 - 8||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A centrally-acting and indirect sympathomimetic appetite suppressant similar to dexamfetamine which can create dependency (WHO 2003). It has been used in the treatment of obese people. Oral administration once or three times a day.
Although there is no published data on its effects on breastfed infants, according to the manufacturer it is excreted in breastmilk, meaning its use during breastfeeding is not recommended. (UDS 2011)
The lack of published pharmacological data makes it difficult to accurately predict its possible excretion in breastmilk.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives are preferable, especially during the neonatal period and in case of prematurity.
It produces insomnia, anorexia, nervousness and major side effects, especially cardiac effects (Cheung 2013). There have been reports of psychosis and hallucinations and a case of ketoacidosis in a woman affected by diabetes. (Branis 2015)
There is a risk it may become a drug of abuse (WHO 2003) and was withdrawn from sale in the European Union in 2000. (AEMPS 2000)
None of the current pharmacological treatments for obesity are indicated for use in pregnant or breastfeeding women. (Rodríguez 2016)
There is good quality evidence that exclusive breastfeeding helps to regain pre-pregnancy weight earlier than if breastfeeding is partial (mixed) or there is no breastfeeding, and that prolonged breastfeeding helps maintain that loss and as well as body fat loss. (Jayasinghe 2021, Schalla 2017, López 2016, Jarlenski 2014, Sámano 2013, Neville 2014, Hatsu 2008, Dewey 2004, 2001 y 1993, Kramer 1993)